SickKids helping to expand access to genomic using the C-GUIDE measurement tool in the iHope program
SickKids is providing the C-GUIDE™ tool evaluation of iHope's genomic testing for the diagnosis, care, and well-being ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...
Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy according to hedge funds. On January 23, Bausch Health announced the results of its global Phase 3 RED-C ...
Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Novel KIF18A inhibitor, ATX-295, shows enriched activity in ovarian and TNBC preclinical models with whole genome doubling First-in-class DHX9 inhibitor, ATX-559, demonstrates potent activity in ...
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...
News Medical on MSN
11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy
March 23-25, 2026 | San Diego, CA The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies. The meeting continues as the longest ...
WALTHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the ...
Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from ...
Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...
PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results